Darren Cline
Director/Board Member presso PYXIS ONCOLOGY, INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Profilo
Darren S.
Cline is an Independent Director at Ipi Legacy Liquidation Co., Pliant Therapeutics, Inc., and Pyxis Oncology, Inc. He previously served as the President, Chief Executive Officer & Director at Epygenix Therapeutics, Inc. He also held positions as a Marketing Director at Amgen, Inc., Executive Director-Sales at Alexion Pharmaceuticals, Inc., Director at Acadia Realty Trust, Cascadian Therapeutics LLC, and Stemline Therapeutics, Inc., and Vice President-Market Access at InterMune, Inc. Additionally, he was the Chief Commercial Officer at Greenwich Biosciences, Inc. and GW Pharmaceuticals Ltd.
He spent a significant portion of his career at Seagen Inc., where he held the position of Senior Vice President-Commercial.
Mr. Cline obtained his undergraduate degree from San Diego State University and holds an MBA from Pepperdine University and Pepperdine Graziadio Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
0.43% | 26/03/2024 | 251 405 ( 0.43% ) | 1 M $ | 31/03/2024 |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Darren Cline
| Società | Posizione | Inizio |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Director/Board Member | 01/09/2021 |
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 06/03/2023 |
| IPI LEGACY LIQUIDATION CO | Director/Board Member | 12/04/2023 |
Precedenti posizioni note di Darren Cline
| Società | Posizione | Fine |
|---|---|---|
Epygenix Therapeutics, Inc.
 Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Epygenix Therapeutics, Inc. manufactures drugs products that treat dravet syndrome and genetic epilepsies. It offers Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome. The company was founded by Hahn-Jun Lee and is headquartered in Paramus, NJ. | Chief Executive Officer | 01/03/2023 |
Greenwich Biosciences, Inc.
 Greenwich Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Greenwich Biosciences, Inc. develops and markets cannabinoid prescription medicines through online. The company is headquartered in Carlsbad, CA. | Corporate Officer/Principal | 01/12/2021 |
| GW PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/12/2021 |
| SEAGEN INC. | Corporate Officer/Principal | 01/03/2019 |
| INTERMUNE INC | Corporate Officer/Principal | 01/07/2010 |
Formazione di Darren Cline
| San Diego State University | Undergraduate Degree |
| Pepperdine Graziadio Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ACADIA REALTY TRUST | Finance |
| IPI LEGACY LIQUIDATION CO | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Greenwich Biosciences, Inc.
Greenwich Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Greenwich Biosciences, Inc. develops and markets cannabinoid prescription medicines through online. The company is headquartered in Carlsbad, CA. | Health Technology |
Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Epygenix Therapeutics, Inc. manufactures drugs products that treat dravet syndrome and genetic epilepsies. It offers Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome. The company was founded by Hahn-Jun Lee and is headquartered in Paramus, NJ. | Health Technology |
- Borsa valori
- Insiders
- Darren Cline
